Skip to main content
SpringerLink
Log in

Die systemische Chemotherapie des Leberkarzinoms

  • Chapter
Book cover Neue Entwicklungen in der Therapie von Lebertumoren

Zusammenfassung

Das primäre Leberzellkarzinom ist ein relativ seltener Tumor mit einer jährlichen Inzidenz von 1 – 7/100000 Einwohner. Allerdings ist das Leberkarzinom in Südostasien und weiteren Ländern mit hoher Hepatitisdurchseuchung viel häufiger mit z. B. 65% aller Malignome bei Männern und 31% bei den Frauen in Mozambique; auch China und Japan haben eine sehr hohe Inzidenz des HCC’s entsprechend der höheren Hepatitis-B-Infektionsrate. In diesen Ländern erkranken auch deutlich jüngere Menschen im Alter zwischen 30 und 40 Jahren, während der Erkrankungsgipfel in Deutschland bei 50 Jahren liegt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Al-Idrissi H, Ibrahim E, Satir A et al. (1985) Primary hepatocellular carcinoma in the Eastern Province of Saudi Arabia: Treatment with combination chemotherapy using 5-fluorouracil, adriamycin, and mitomycin-C. Hepatogastroenterology 32:8–10

    CAS  PubMed  Google Scholar 

  2. Amrein P, Richards F, Coleman M et al. (1984) Phase II trial of amsacrine in patients with hepatoma: A Cancer and Leukemia Group Study. Cancer Treat Rep 68:923–924

    CAS  PubMed  Google Scholar 

  3. Baker LH, Saiki JH, Jones SE et al. (1977) Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma. A Southwest Oncology Group Study. Cancer Treat Rep 61:1595–1597

    CAS  PubMed  Google Scholar 

  4. Barbare J, Ballet F, Petit J et al. (1984) Carcinoma hepatocellulaire sue cirrhose: Traitment par la doxorubicine. Essarile phase II. Bull Cancer (Paris) 71:442–445

    CAS  Google Scholar 

  5. Bezwoda W, Derman D (1982) Treatment of advanced malignant hepatoma with adriamycin or AMSA in combination with VM-26 plus 5-FU (Abstr). Proc Am Soc Clin Oncol 1:91

    Google Scholar 

  6. Brennan M, Talley R et al. (1964) Critical analysis of 594 cancer patients treated with 5-fluorouracil. In: Plattner A (ed) Proceedings of the International Symposium on Chemotherapy of Cancer, Elsevier North-Holland, Amsterdam, pp 118–149

    Google Scholar 

  7. Bukowski R, Legha S, Saki J et al. (1982) Phase II trial of m-AMSA in hepatocellular carcinoma: A Southwest Oncology Group Study. Cancer Treat Rep 66:1651–1652

    CAS  PubMed  Google Scholar 

  8. Cavalli F, Rozencweig M, Renard J et al. (1981) Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17:1079–1082

    Article  CAS  PubMed  Google Scholar 

  9. Ceulemans F, Baurain R, Geubel A, Lesur B, Rolin-van Swieten D, Truet A (1987) Pilotage des anthracyclines et hepatomas (Targeting of anthracyclines and hepatomas). Pathol Biol (Paris) 35 (1):61–68

    CAS  Google Scholar 

  10. Cheirsilpa A, Leelasethakul S, Auethaveekiat V, Maoleekulprioj S, Kangsumrit N, Thanakaravit P, Phanthumjida P (1989) High-dose mitomycin-C: Activity in hepatocellular carcinoma. Cancer Chemother Pharmacol 24:50–53

    Article  CAS  PubMed  Google Scholar 

  11. Cheng E, Chun H, Schiff C et al. (1985) Phase II trial of oral 4’demethoxydauno-rubicin (DMDR) in patients (pts) with primary liver carcinoma (PLC). Proc Am Soc Clin Oncol (Abstr) 4:88

    Google Scholar 

  12. Cheng E, Lightdale C, Young C et al. (1983) A phase II trial of (m-AMSA) 4′-9(acridinylamino)-methanesulfon-m-anisidide in primary liver cancer. Am J Clin Oncol 6:211–213

    Article  CAS  PubMed  Google Scholar 

  13. Chlebowski R, Brzechwa-Adjunkiewicz A, Cowden A et al. (1984) Doxorubicin (75 mg/m2) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 68:487–491

    CAS  PubMed  Google Scholar 

  14. Chlebowski R, Chan K, Tong M et al. (1981) Adriamycin and methyl-CCNU. Combination therapy in hepatocellular carcinoma: Clinical and pharmacokinetic aspects. Cancer 48:1088–1095

    Article  CAS  PubMed  Google Scholar 

  15. Choi T, Lee N, Wong J (1984) Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 53:401–405

    Article  CAS  PubMed  Google Scholar 

  16. Cochrane A, Muray-Lyon I, Brinkly D et al. (1977) Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer 40:609–614

    Article  CAS  PubMed  Google Scholar 

  17. Damrousak KC et al. (1973) Vinblastine in the treatment of carcinoma of the liver. J Med Assoc Thai 56:370–372

    Google Scholar 

  18. Danopoulus ED, Danopulou IE (1981) Eleven years experience of oral urea treatment in liver malignancies. Clin Oncol 7:281

    Google Scholar 

  19. Davis BB, Ecco DA van, Leone LA et al. (1986) Phase II trial of mitoxantrone in advanced primary liver cancer. A cancer and leukemia group B study. Cancer Treat Rep 70:1125–1126

    CAS  PubMed  Google Scholar 

  20. Davis H, Ramirez G, Arnsfield F (1974) Adenocarcinomas of stomach, pancreas, liver and bilary tracts: Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 33:193–197

    Article  PubMed  Google Scholar 

  21. Falkson G, Coetzer B (1985) Phase II studies of mitoxantrone in patients with liver cancer. Invest New Drugs 3:187–189

    Article  CAS  PubMed  Google Scholar 

  22. Falkson G, Coetzer B (1987) Chemotherapy of primary liver cancer. In: Okuda K, Ushak KG (eds) Neoplasms of the liver. Springer, Berlin Heidelberg New York Tokyo, pp 321–326

    Google Scholar 

  23. Falkson G, Coetzer B, Klaassen D (1981) A phase II study of m-AMSA in patients with primary liver cancer. Cancer Chemother Pharmacol 6:127–129

    CAS  PubMed  Google Scholar 

  24. Falkson G, Coetzer BJ, Terblance APS (1984) Phase II mitoxantrone in patients with primary liver cancer. Cancer Treat Rep (Suppl 10) 68:1311–1312

    CAS  PubMed  Google Scholar 

  25. Falkson G, MacIntyre J, Coetzer B et al. (1984) Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol (Suppl 6) 2: 581–584

    CAS  PubMed  Google Scholar 

  26. Falkson G, Moertel C, Lavin P et al. (1978) Chemotherapy studies in primary liver cancer: A prospective randomized clinical trial. Cancer 42:2149–2156

    Article  CAS  PubMed  Google Scholar 

  27. Falkson G, Ryan LM, Johnson LA, Simson IW et al. (1987) A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 60:2141–2145

    Article  CAS  PubMed  Google Scholar 

  28. Falkson G, MacIntyre JM, Charles G et al. (1984) Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 54:970–977

    Article  CAS  PubMed  Google Scholar 

  29. Falkson G, Hoff D von, Klaassen D et al. (1980) A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group Pilot Study. Cancer Chemother Pharmacol 4:33–36

    Article  CAS  PubMed  Google Scholar 

  30. Forbes A, Wilkinson ML, Iqbal MJ, Johnson PJ, Williams R (1987) Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in fre 5 alphadihydrotestosterone. Eur J Cancer Clin Oncol 23 (11):1659–1664

    Article  CAS  PubMed  Google Scholar 

  31. Forbes A, Williams R (1987) Chemotherapy and radiotherapy of malignant hepatic tumors, Baillières Clin Gastroenterol 1 (1):151–169

    Article  CAS  PubMed  Google Scholar 

  32. Gailani S, Holland JF, Falkson G et al. (1972) Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside. Cancer 29:1308–1313

    Article  CAS  PubMed  Google Scholar 

  33. Hoechster HS, Green MD, Speyer S et al. (1985) 4-Epidoxorubicin (epirubicin): Activity in hepatocellular carcinoma. J Clin Oncol (Suppl 3) 3:1535–1540

    Google Scholar 

  34. Johnson P, Thomas H, Williams R et al. (1978) Induction of remission in HCC with doxorubicin. Lancet 1:1006–1009

    Article  CAS  PubMed  Google Scholar 

  35. Joishy SK, Bennett JM, Balasegaram M et al. (1982) Clinical and chemotherapeutic study of hepatocellular carcinoma in Malaysia — A comparison with African and American patients. Cancer 50:1065–1069

    Article  CAS  PubMed  Google Scholar 

  36. Kehayoblou K, Athanasiades P, Hartzoulakis I, Papavasiliou C (1980) A comparative study of the effect of adriamycin versus adriamycin-mitomycin C on primary hepatocellular carcinoma (PHC). Int Congr Ser 484:239–242

    Google Scholar 

  37. Kennedy P, Lahane D, Smith F et al. (1977) Oral fluorouracil therapy of hepatoma. Cancer 39:1930–1935

    Article  CAS  PubMed  Google Scholar 

  38. Lai CL, Wu PC, Lok AS, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479–483

    Article  CAS  PubMed  Google Scholar 

  39. Lai CL, Wu PC, Lok ASF (1989) Recombinant α 2interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: A prospective randomised trial. Br J Cancer 60:928–933

    Article  CAS  PubMed  Google Scholar 

  40. Lai KH, Tsai YT, Lee SD et al. (1986) Clinical trial of doxofluoridine in the treatment of primary hepatocellular carcinoma. Cancer Treat Rep 70:1339–1340

    CAS  PubMed  Google Scholar 

  41. Link J, Bateman J, Paroly W et al. (1977) 5-Fluorouracil in hepatocellular carcinoma — Report of twentyone cases. Cancer 39:1936–1939

    Article  CAS  PubMed  Google Scholar 

  42. Lokich J (1987) Chemotherapy for hepatoma. Sci Pract Surg 8:239–253

    Google Scholar 

  43. MacIntyre K, Vogel C, Primack A et al. (1976) Effect of surgical and chemotherapeutic treatment on alpha fetoprotein levels in patients with hepatocellular carcinoma. Cancer 37:677–683

    Article  Google Scholar 

  44. Melia W, Johnson P, Williams R (1987) Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71:1213–1216

    CAS  PubMed  Google Scholar 

  45. Melia W, Johnson P, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP-16 with adriamycin. Cancer 51:206–221

    Article  CAS  PubMed  Google Scholar 

  46. Melia WM, Westaby D, Williams R (1981) Diamminodichloride platinum (cisplatinum) in the treatment of hepatocellular carcinoma. Clin Oncol 7:275–280

    CAS  PubMed  Google Scholar 

  47. Morstyn G, Ihde D, Eddy J et al. (1983) Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin. Am J Clin Oncol 6:547–551

    CAS  PubMed  Google Scholar 

  48. Muggia FM, Green MD (1985) New chemotherapeutic agents in liver cancer. Dev Oncol 30:217–224

    Google Scholar 

  49. Okuda K, Ohtsuki T, Obata H et al. (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients. Cancer 56:918–928

    Article  CAS  PubMed  Google Scholar 

  50. Olweny CL, Katongole-Mbidde E, Bahendeka S et al. (1980) Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 46:2717–2722

    Article  CAS  PubMed  Google Scholar 

  51. Oon CJ, Chua EJ, Foong W et al. (1980) Adriamycin in the treatment of resectable and unresectable primary hepatocellular carcinoma. Ann Acad Med Singapore 9:256–259

    CAS  PubMed  Google Scholar 

  52. Order S, Sillwagon GB, Klein J et al. (1985) Iodine-131 antiferritin, a new treatment modality in hepatoma: Radiation Therapy Oncology Group Study. J Clin Oncol 3:1573

    CAS  PubMed  Google Scholar 

  53. Order S, Pajak T, Klein J et al. (1989) A randomized prospective trial in nonresectable hepatoma comparing adriamycin and 5-fluorouracil + 131-I antiferritin: An RTOG study. Proc Annu Meet Am Soc Clin Oncol 8:A381

    Google Scholar 

  54. Paliard R, Clement G, Saez S et al. (1984) Traitment du carcinome hepatocellulaire par ale tamoxifene. Gastroenterol Clin Biol 8:680–681

    CAS  PubMed  Google Scholar 

  55. Park B, Koo J, Lee J, Yoon J (1987) Combination chemotherapy of primary hepatocellular carcinoma with doxorubicin, cisplatin, and 5-fluorouracil (meeting abstract). EORTC Symposium on Recent Advances in Cancer Management, Hong Kong 1987, p 15

    Google Scholar 

  56. Perry DJ, Ecco DA van, Mick R (1987) A phase II study of deoxydoxorubicin in patients with advanced liver cancer. Cancer Treat Rep 71:1117–1118

    CAS  PubMed  Google Scholar 

  57. Peters WP, Henner WD, Grochow LB et al. (1987) Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47:6402–6406

    CAS  PubMed  Google Scholar 

  58. Ravry MJR, Omura GA, Bartolucci AA (1984) A phase II evaluation of hepatocellular carcinoma of epidoxorubicin plus bleomycin in hepatocellular carcinoma: A Southeastern Cancer Study Group Trial. Cancer Treat Rep 68:1517–1518

    CAS  PubMed  Google Scholar 

  59. Ravry MJR, Omura GA, Bartolucci AA et al. (1986) Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiosarcoma: A Southwestern Cancer Study Group Trial. Cancer Treat Rep 70:311–312

    CAS  PubMed  Google Scholar 

  60. Razis DV, Petounis A, Hadziyannis SJ (1986) Modern trends in the management of hepatocellular carcinoma. Drugs Exp Clin Res 12 (81–3):181 – 190

    Google Scholar 

  61. Schlumberger JF (1987) A propos de la lettre de Mal et coll.: Traitement de 25 malades atteints de carcinome hépatocellulaire (CHC) par un antiandrogène, l’acétate de cyprotérone (Androcur). Gastroenterol Clin Biol 11:835

    CAS  PubMed  Google Scholar 

  62. Shiu W, Mok SD, Tsao S et al. (1986) Phase II trial of epirubicine in hepatoma. Cancer Treat Rep 70:1035–1036

    CAS  PubMed  Google Scholar 

  63. Shiu W, Mok SD, Leung N, Li M, Zacharia A, Li A, Martin C (1987) Phase 2 study of high dose etoposide (VP16–213) in hepatocellular carcinoma. Jpn J Clin Oncol 17:113–115

    CAS  PubMed  Google Scholar 

  64. South Africa Primary Liver Cancer Research Group (1967) Malignant hepatoma — controlled therapeutic trials. S Afr Med J 41:309–314

    Google Scholar 

  65. Thonprasert S, Klunklin K, Phornphutkul K et al. (1988) Phase II study of ifosfamide (Holoxan) in hepatoma. Eur J Cancer Clin Oncol 24:1795–1796

    Article  Google Scholar 

  66. Treat JA, Ahlgren JD, Woolley PV (1986) Cancers of the large bowel and hepatobiliary system. Cancer Chemother 8:378–387

    Google Scholar 

  67. Umsawasdi T, Chainuvati T, Viranuvatto V (1978) Combination chemotherapy of hepatocellular carcinoma (HCC) with 5-fluorouracil (5-FU) and mitomycin-C (MMC) (Abstr). Proc Am Assoc Cancer Res 19:193

    Google Scholar 

  68. Vogel C, Adamson R, DeVita V et al. (1972) Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma. Cancer Chemother Rep 56:249–258

    CAS  PubMed  Google Scholar 

  69. Yang BH, Lu JZ, Tang ZY, Luo WW, Teng ZZ (1986) Randomized clinical trial of cis-platinum diamminechloride (PDD) in the treatment of hepatocellular carcinoma (HCC). Chung Hua Chung Liu Tsa Chih 8 (6):467–469

    CAS  PubMed  Google Scholar 

  70. Yoshino M, Obazaki N, Yoshida T et al. (1989) A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. Jpn J Clin Oncol 19:120–122

    CAS  PubMed  Google Scholar 

  71. Zaniboni A, Simoncini E, Marpicati, Marini G (1988) Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma. Br J Cancer 57:319

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik, MHH, Konstanty-Gutschow-Straße 8, W-3000, Hannover, Deutschland

    E. Schmoll, H.-J. Schmoll, G. Böhmer, H. Wilke & H. Poliwoda

Authors
  1. E. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.-J. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Böhmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Poliwoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chirurgische Klinik, Ruprecht-Karls-Universität, Im Neuenheimer Feld 110, W-6900, Heidelberg, Deutschland

    Christian Herfarth  & Peter Schlag  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schmoll, E., Schmoll, HJ., Böhmer, G., Wilke, H., Poliwoda, H. (1991). Die systemische Chemotherapie des Leberkarzinoms. In: Herfarth, C., Schlag, P. (eds) Neue Entwicklungen in der Therapie von Lebertumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76425-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76425-7_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76426-4

  • Online ISBN: 978-3-642-76425-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation